Molecular and Serological Prevalence of HCMV in Iranian Patients with Breast Cancer

Nakhaie, Mohsen; Charostad, Javad; Azaran, Azarakhsh; Arabzadeh, Seyyed Ali Mohammad; Motamedfar, Azim; Iranparast, Sara; Ahmadpour, Fatemeh; Talaeizadeh, Abdolhasan; Makvandi, Manoochehr

doi:10.31557/APJCP.2021.22.7.2011

Molecular and Serological Prevalence of HCMV in Iranian Patients with Breast Cancer

Document Type : Research Articles

Authors

¹ Cancer Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

² Department of Medical Virology School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

³ Department of Medical Microbiology, Kerman University of Medical Sciences, Kerman, Iran.

⁴ Department of Nuclear Medicine, School of Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical sciences, Ahvaz, Iran.

⁵ Department of Immunology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

⁶ Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

10.31557/APJCP.2021.22.7.2011

Abstract

Background: Human cytomegalovirus (HCMV) is prevalent viral infection involved in several human cancers including breast cancer. The presence of HCMV genome in breast cancer tissue and footprint of viral last exposure patient’s serum are considered as important factor in the process of breast cancer development. Objectives: This study aimed to investigate molecular and serological epidemiology of HCMV in patients with breast cancer in Iran for first time. Methods: In our case-control study, 98 samples of breast tissue, including 49 cancerous (case) and 49 adjacent non-cancerous tissue were collected (control). In addition, we collected sera samples from all patients (n=49) and healthy individual (n=49). Seroprevalence of HCMV was assessed by Enzyme-linked immunosorbent assay (ELISA) and detection of HCMV genome was performed using Nested-PCR method. Results: HCMV genome found in 16.3% (8/49) of cases tissue and 2% (1/49) of controls tissue. In patients group, the levels of anti-CMV IgG and IgM were 93.9% and 2% compared to 69.4% and 4.1% in healthy individuals, respectively. There was a statistically difference between the anti-CMV IgG in patients and healthy control (p= 0.002). We found 75% of (6/8) HCMV genome positive PCR samples were also positive for their anti-CMV IgG in cases which was statistically significant (p= 0.01). Conclusions: Our result showed significant presence of HCMV genome and anti-CMV IgG in patients, supporting the role of HCMV in breast cancer.

Keywords

Main Subjects